EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudieNetzwerk-MetaanalyseOpen Access

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data

Simon Shohet iD, Noemi Hummel, Shuai Fu iD, Ian Keyzor iD, Alasdair MacCulloch, Neil Johnson, Jeff Castelli, Ilona Czarny-Ozga, Tahseen Mozaffar iD, Howard Thom iD

Journal of Comparative Effectiveness Research · 2024-10 · 13 (10)

DOI: 10.57264/cer-2024-0045 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Comparative Effectiveness Research, 2024-10. Verfasst von Simon Shohet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Amicus Therapeutics UK Ltd, One Globeside, Fieldhouse Lane, Marlow, SL7 1HZ, UK. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Enzyme Replacement Therapy, 1-Deoxynojirimycin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory function. Until recently, standard of care was enzyme replacement therapy (ERT) with alglucosidase alfa. Second-generation ERTs avalglucosidase alfa (aval) and cipaglucosidase alfa with miglustat (cipa+mig) are now available. Without head-to-head trials comparing aval with cipa+mig, an indirect treatment comparison is informative and timely for understanding potential clinical differentiation. Materials & methods: A systematic literature review was performed to identify relevant studies on cipa+mig and aval. Using patient-level and aggregate published data from randomized controlled trials (RCTs) and phase I/II and open-label extension (OLE) trials, a multi-level network meta-regression was conducted, adjusting for various baseline covariates, including previous ERT duration, to obtain relative effect estimates on 6-minute walk distance (6MWD, meters [m]) and forced vital capacity (FVC, % predicted [pp]). Analyses of two networks were conducted: Network A, including only RCTs, and network B, additionally including single-arm OLE and phase I/II studies.

Results

Network B (full evidence analysis) showed that cipa+mig was associated with a relative increase in 6MWD (mean difference 28.93 m, 95% credible interval [8.26–50.11 m]; Bayesian probability 99.7%) and FVC (2.88 pp [1.07–4.71 pp]; >99.9%) compared with aval. The comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points. Analysis of network A showed that cipa+mig was associated with a relative decrease in 6MWD (-10.02 m [-23.62 to 4.00 m]; 91.8%) and FVC (-1.45 pp [-3.01 to 0.07 pp]; 96.8%) compared with aval.

Conclusion

Cipa+mig showed a favorable effect versus aval when all available evidence was used in the analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIEnzyme Replacement Therapy1-DeoxynojirimycinHumansalpha-GlucosidasesRandomized Controlled Trials as TopicWalk Test

Stichwörter der Autor:innen

Pompe diseasecipaglucosidase alfaindirect treatment comparisonmiglustat

Substanzen

1-Deoxynojirimycinmiglustatalpha-GlucosidasesGAA protein, human

Autor:innen und Institutionen

  • Amicus Therapeutics UK Ltd, One Globeside, Fieldhouse Lane, Marlow, SL7 1HZ, UK.
  • Certara GmbH, Chester Platz 1, 79539, Lörrach, Germany.
  • Certara, Office 610, South Tower, Hong Kong Plaza, No. 283 Huaihai Road Middle, Huangpu District, Shanghai, China.
  • Amicus Therapeutics, Inc., 47 Hulfish St., Princeton, NJ, 08542, USA.
  • Certara, Instytut Arcana sp. z o.o. 17, Kuklinskiego Street, 30-720, Krakow, Poland.
  • Department of Neurology, University of California, 1001 Health Sciences Road, Irvine, CA 92697-3950, USA.

ORCID-Profile: Simon Shohet, Shuai Fu, Ian Keyzor, Tahseen Mozaffar, Howard Thom

Zitieren

APA

Shohet, S., Hummel, N., Fu, S., Keyzor, I., MacCulloch, A., Johnson, N., Castelli, J., Czarny-Ozga, I., Mozaffar, T., & Thom, H. (2024). Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. Journal of Comparative Effectiveness Research, 13(10). https://doi.org/10.57264/cer-2024-0045

Vancouver

Shohet S, Hummel N, Fu S, Keyzor I, MacCulloch A, Johnson N, et al. Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. Journal of Comparative Effectiveness Research. 2024;13(10). doi:10.57264/cer-2024-0045

BibTeX
@article{Shohet2024,
  author = {Shohet, Simon and Hummel, Noemi and Fu, Shuai and Keyzor, Ian and MacCulloch, Alasdair and Johnson, Neil and Castelli, Jeff and Czarny-Ozga, Ilona and Mozaffar, Tahseen and Thom, Howard},
  title = {Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  volume = {13},
  number = {10},
  doi = {10.57264/cer-2024-0045}
}
Kostenlos starten →